SCHEMBL2883770

SCHEMBL2883770

CCOC(=O)c1c(CBr)n(-c2ccccc2)c2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
ALDH1A1 P00352 5/20 0.53
LMNA P02545 3/20 0.53
POLB P06746 1/20 0.53
NPSR1 Q6W5P4 4/20 0.52
TSHR P16473 1/20 0.52
MAPT P10636 5/20 0.51
GAA P10253 2/20 0.51
THRB P10828 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KDM4E B2RXH2 2/20 0.49
P4HB P07237 1/20 0.48
HTT P42858 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
TP53 P04637 1/20 0.47
PTGES O14684 1/20 0.46
PDE4D Q08499 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28776310 0.90 RECQL (0.60) RECQLMEN1KMT2AALDH1A1LMNA
SCHEMBL25944688 0.87 KMT2A (0.57) RECQLMEN1KMT2AALDH1A1LMNA
SCHEMBL25938648 0.85 RECQL (0.60) RECQLMEN1KMT2AALDH1A1LMNA
SCHEMBL25938710 0.85 RECQL (0.60) RECQLMEN1KMT2AALDH1A1LMNA
SCHEMBL2885250 0.84 MEN1 (0.74) RECQLMEN1KMT2AALDH1A1NPSR1
SCHEMBL25941522 0.83 KDM4E (0.60) MEN1KMT2AALDH1A1LMNATSHR
SCHEMBL2881205 0.81 ALDH1A1 (0.52) RECQLMEN1KMT2AALDH1A1LMNA
SCHEMBL25938715 0.80 KMT2A (0.69) RECQLMEN1KMT2AALDH1A1LMNA
SCHEMBL25938652 0.80 RECQL (0.55) RECQLMEN1KMT2AALDH1A1LMNA
SCHEMBL14848302 0.80 RECQL (0.81) RECQLMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4209492-A1 COMPOUND FOR TREATING THROMBOTIC DISEASES Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2023-07-12 EP disclosed
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 RECQL 3437/4885MEN1 4211/4885KMT2A 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.